Mirati Therapeutics, Inc. (MRTX)
| Market Cap | 10.29B |
| Revenue (ttm) | 12.22M |
| Net Income (ttm) | -329.23M |
| Shares Out | 44.61M |
| EPS (ttm) | -7.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $195.47 |
| Previous Close | $202.90 |
| Change ($) | -7.43 |
| Change (%) | -3.66% |
| Day's Open | 199.69 |
| Day's Range | 194.05 - 204.97 |
| Day's Volume | 328,375 |
| 52-Week Range | 66.01 - 249.42 |
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference ...
Leveraging sound science and prudent cancer treatment, Mirati is growing robustly. The two lead drugs (sitravatinib and Adagrasib) are rapidly advancing for different cancer indications.
It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2...
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29...
SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended Septe...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...
SAN DIEGO, Oct. 30, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of it...
Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a pr...
Promising results from a study of its cancer drug pushed Mirati Therapeutics Inc. (NASDAQ:MRTX) to an all-time high Monday. Shares of the San Diego-based biotech hit more than $210 and are at ...
Which one of these biotech stocks has a better chance to provide market-beating gains?
SAN DIEGO, Oct. 26, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares ...
Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The biotech's positive clinical results announced on Sunday prompted analysts to boost their price targets on the stock.
Tiny Mirati Therapeutics posted positive preliminary data on a colorectal and lung cancer drug therapy in competition with drug giant Amgen, sending MRTX stock soaring to an all-time high. The...
SAN DIEGO, Oct. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant KRA...
Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of invest...
SAN DIEGO, Oct. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical data from adagrasib (MRTX849), t...
LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.
Mirati achieves positive results in phase 2 open-label study using sitravatinib to treat patients with metastatic or advanced urothelial carcinoma who have the KRAS mutation.
LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.
SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study ...
INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 17...
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 13, 2020 /PRNewswire/ -- Strata Oncology, Inc.
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.
ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 6, 2020 /PRNewswire/ --Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mirati Therapeutics, Inc. ("Mirati" ...
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41st Annual Goldman Sachs Global ...
SAN DIEGO, May 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief Med...
SAN DIEGO, May 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's ...
Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Mirati Therapeutics, Inc.: Cracking KRAS Is Harder Than It Looks
Mirati Therapeutics Inc (NASDAQ: MRTX) shares were seeing weakness Tuesday after short seller Kerrisdale Capital released a bleak report concerning its two investigational assets.
Healthcare bargain hunters can find good values in quality low-priced stocks.
Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.
Results from a combination study breathed life into the company's sitravatinib program.
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
Investors need to pay close attention to Mirati (MRTX) stock based on the movements in the options market lately.
Mirati Therapeutics: A Classic Philip Fisher Growth Stock
MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.
Both biotechs are developing revolutionary new cancer drugs, but which stock is better for your portfolio right now?
This time, its own clinical trial is pushing the biotech higher.
About MRTX
Mirati Therapeutics, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It h... [Read more...]
| Industry Biotechnology | IPO Date Jun 29, 2004 |
| CEO Charles Baum | Employees 111 |
| Stock Exchange NASDAQ | Ticker Symbol MRTX |
Financial Performance
In 2019, MRTX's revenue was $3.34 million, a decrease of -74.20% compared to the previous year's $12.93 million. Losses were -$213.26 million, 116.7% more than in 2018.
Analyst Forecasts
According to 15 analysts, the average rating for MRTX stock is "Buy." The 12-month stock price forecast is 245.92, which is an increase of 25.81% from the latest price.